Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers

Charles A Kunos, Stephen J Andrews, Kathleen N Moore, Hye Sook Chon, S Percy Ivy, Charles A Kunos, Stephen J Andrews, Kathleen N Moore, Hye Sook Chon, S Percy Ivy

Abstract

Uterine cervix or vaginal cancers have inherent overactivity of ribonucleotide reductase (RNR), making these cancers rational targets for therapy based on interruption of cisplatin-radiotherapy-induced DNA damage repair. We conducted a pilot, open-label randomized phase II trial to evaluate the efficacy and safety of cisplatin-radiotherapy with or without triapine, a small molecule with RNR-inhibitory activity, in patients with advanced-stage uterine cervix or vaginal cancers (NCT01835171), as a lead in to a randomized phase III study (NCT02466971). A total of 26 women were randomly assigned to receive 6 weeks of daily radiotherapy followed by brachytherapy (80 Gy) and once-weekly cisplatin (40 mg m-2)-with or without three-times weekly intravenous triapine (25 mg m-2)-in one 56-days cycle. Primary end points were metabolic complete response by positron emission tomography and safety. Additional end points included the rate of clinical response, rate of methemoglobinemia, and progression-free survival. The addition of triapine to cisplatin-radiotherapy improved the rate of metabolic complete response from 69 to 92% (P = 0.32) and raised the 3-year progression-free survival estimate from 77 to 92% (hazard ratio for progression, 0.30; P = 0.27). The most frequent grade 3 or 4 adverse events in either treatment group included reversible leukopenia, neutropenia, fatigue, or electrolyte abnormalities. No significant differences were seen between the two groups in the rate of adverse events. Symptomatic methemoglobinemia was not encountered after triapine infusion. In conclusion, the addition of triapine to cisplatin-radiotherapy improved the rate of metabolic complete response in patients with advanced-stage uterine cervix or vaginal cancers without significant toxicity. A phase III trial adequately powered to evaluate progression-free and overall survival is underway (NCT02466971).

Keywords: cervical cancer; cisplatin; radiotherapy; randomized phase II; triapine; uterine cervix cancer.

Copyright © 2019 Kunos, Andrews, Moore, Chon and Ivy.

Figures

Figure 1
Figure 1
Enrollment, randomization, and follow-up of the study patients.

References

    1. International Agency for Research on Cancer GLOBOCAN 2018 Cancer Incidence and Mortality Worldwide. New York, NY: World Health Organization; (2019). Available online at: (accessed May 30, 2019).
    1. American Cancer Society Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society; (2019).
    1. Kunos C, Radivoyevitch T, Abdul-Karim FW, Faulhaber P. 18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response. Int J Gynecol Cancer. (2011) 21:1117–23. 10.1097/IGC.0b013e31821dc8b5
    1. Kunos CA, Radivoyevitch T, Kresak A, Dawson D, Jacobberger J, Yang B, et al. . Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. Int J Gynecol Cancer. (2012) 22:1463–9. 10.1097/IGC.0b013e318270577f
    1. Kunos CA, Winter K, Dicker AP, Small W, Jr, Abdul-Karim FW, Dawson D, et al. . Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer. (2013) 23:615–21. 10.1097/IGC.0b013e31828b4eb5
    1. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, et al. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res. (2010) 16:1298–306. 10.1158/1078-0432.Ccr-09-2469
    1. Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, et al. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol. (2013) 130:75–80. 10.1016/j.ygyno.2013.04.019
    1. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. . Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. (2002) 20:966–72. 10.1200/jco.2002.20.4.966
    1. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. (1999) 340:1144–53. 10.1056/nejm199904153401502
    1. Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, et al. . Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. (2007) 25:2804–10. 10.1200/jco.2006.09.4532
    1. Souhami L, Seymour R, Roman TN, Stanimir GW, Trudeau M, Clark BG, et al. . Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys. (1993) 27:871–8.
    1. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, III, et al. . Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. (1999) 340:1154–61. 10.1056/nejm199904153401503
    1. Kunos CA, Radivoyevitch T. Molecular strategies of deoxynucleotide triphosphate supply inhibition used in the treatment of gynecologic malignancies. Gynecol Obstet (Sunnyvale). (2011) Suppl. 4:1–5. 10.4172/2161-0932.S4-001
    1. Kunos CA. Therapeutic mechanisms of treatment in cervical and vaginal cancer. Oncol Hematol Rev. (2012) 8:55–60.
    1. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem. (2006) 281:7834–41. 10.1074/jbc.M512894200
    1. Reichard P, Eliasson R, Ingemarson R, Thelander L. Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase. J Biol Chem. (2000) 275:33021–6. 10.1074/jbc.M005337200
    1. Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, et al. . In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res. (2006) 12:2912–8. 10.1158/1078-0432.Ccr-05-2860
    1. Kunos CA, Chiu SM, Pink J, Kinsella TJ. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res. (2009) 172:666–76. 10.1667/rr1858.1
    1. Kunos CA, Radivoyevitch T, Pink J, Chiu SM, Stefan T, Jacobberger J, et al. . Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. (2010) 174:574–81. 10.1667/rr2273.1
    1. Kunos CA, Ferris G, Pyatka N, Pink J, Radivoyevitch T. Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers. Radiat Res. (2011) 176:425–33. 10.1667/RR2556.1
    1. Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, et al. . Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol. (2002) 50:223–9. 10.1007/s00280-002-0480-0
    1. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone administered by 96-hour intravenous continuous infusion. J Clin Oncol. (2004) 22:1553–63. 10.1200/jco.2004.07.158
    1. Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies. Cancer Chemother Pharmacol. (2017) 79:201–7. 10.1007/s00280-016-3200-x
    1. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Jr, et al. . Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. (1999) 17:1339–48. 10.1200/jco.1999.17.5.1339
    1. Stehman FB, Bundy BN, Kucera PR, Deppe G, Reddy S, O'Connor DM. Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I-II trial of the Gynecologic Oncology Group. Gynecol Oncol. (1997) 66:262–7. 10.1006/gyno.1997.4761
    1. Kunos CA, Radivoyevitch T, Ingalls ST, Hoppel CL. Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia. Fut Oncol. (2012) 8:145–50. 10.2217/fon.11.147
    1. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. (1999) 35:1773–82.
    1. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. . Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. (2006) 47:1059–66.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. (2000) 92:205–16. 10.1093/jnci/92.3.205
    1. Kunos CA, Ivy SP. Triapine radiochemotherapy in advanced stage cervical cancer. Front Oncol. (2018) 8:149. 10.3389/fonc.2018.00149

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren